Opus Genetics has shared encouraging early results from its ongoing Phase 1/2 clinical trial for OPGx-BEST1, a potential one-time gene therapy for people with BEST1-related retinal disease. All five patients enrolled in the clinical trial had clinically meaningful improvement in visual function, according to Opus Genetics. The greatest functional improvements were observed in participants with less advanced disease.

Rss Apple Podcaster
Podden och tillhörande omslagsbild på den här sidan tillhör Foundation Fighting Blindness. Innehållet i podden är skapat av Foundation Fighting Blindness och inte av, eller tillsammans med, Poddtoppen.